[The new agent IMP-1524: design, acute toxicity, and antihymenolepidous activity].
F S
FS
Mikhaĭlitsyn
M N
MN
Lebedeva
G A
GA
Gitsu
D G
DG
Baiandina
B A
BA
Astaf'ev
N D
ND
Lychko
N A
NA
Uvarova
A S
AS
Naĭdenova
D000284:Administration, Oral; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use* / Q000633:toxicity; D001549:Benzamides / Q000737:chemistry / Q000627:therapeutic use* / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D006925:Hymenolepiasis / Q000188:drug therapy*; D048189:Hymenolepis nana; D051379:Mice; D015394:Molecular Structure; D013329:Structure-Activity Relationship; D013830:Thiadiazoles / Q000737:chemistry / Q000627:therapeutic use* / Q000633:toxicity
D000871:Anthelmintics; D001549:Benzamides; C502961:N-(3-chloro-4-(benzo-2,1,3-thiadiazol-5-yloxy)phenyl)-3,5-dibromobenzamide; D013830:Thiadiazoles